[Solifenacin in the treatment of overactive bladder: results of a randomized double-blind, placebo-controlled study].
The article presents the results of the evaluation of clinical efficacy and safety of the M-cholinoblocker solifenacin in the treatment of symptoms of overactive bladder (OAB). The study included 24 women aged from 47 to 69 years with symptoms of OAB lasting more than 3 months. It is shown that solifenacin at a dose of 5 mg reduces the quality of urinary urgency, improves the condition according to assessment of degree of discomfort due to symptoms of the OAB, treatment satisfaction and condition of the bladder.
I S
IS
Ibinaeva
I A
IA
Apolikhina
F N
FN
Makhmedzhanova
S Z
SZ
Muslimova
D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D011812:Quinuclidines / Q000008:administration & dosage*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate